Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Apr 19, 2024
Episode
214
Soundcloud
Share
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which included patients with resected stage II/III NSCLC with an ALK fusion.
Guest
Benjamin Solomon
PhD, MBBS, FRACP
Professor and Consultant Medical Oncologist
Peter MacCallum Cancer Center
IASLC Board of Directors
